Nonstandard abbreviations used {#nomen0010}
==============================

CEACAM1

:   Carcinoembryonic antigen-related cell adhesion molecule 1

*Ceacam1(Cc1)*

:   Gene encoding CEACAM1 protein

*Cc1*^*−/−*^

:   Global *Ceacam1* null mouse

*Cc1*^*−/−xliver*+^

:   *Cc1*^*−/−*^ mouse with liver-specific rescuing of the rat *Ceacam1* gene

ET-1

:   Endothelin-1

*Etar* and *Etbr*

:   mRNA of Endothelin-1 receptor-A and -B

eNOS

:   Endothelial nitric oxide synthase

FASN

:   Fatty acid synthase

*Icam-1*

:   mRNA of Intercellular cell adhesion molecule-1

IRβ

:   β subunit of the insulin receptor

m*Cc1*

:   Mouse *Cc1* gene

NO

:   Nitric oxide

RAS

:   Renin--angiotensin--aldosterone system

r*Cc1*

:   Rat *Cc1* gene

VCAM-1

:   Vascular cell adhesion molecule-1

1. Introduction {#sec1}
===============

Insulin resistance, heralded by hyperinsulinemia with altered glucose and lipid homeostasis [@bib1] and diminished regulation of nutrient delivery through the microcirculation [@bib2], is linked to endothelial dysfunction [@bib3], [@bib4], [@bib5]. In the vascular endothelium, insulin resistance exerts a pro-hypertensive/atherogenic effect by impairing nitric oxide (NO) production, increasing the vasoconstrictor tone through endothelin-1 activity, and inducing the expression of pro-inflammatory cell adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) [@bib5]. Decreased NO bioavailability is accompanied by reduced vasodilation in response to stimuli, such as acetylcholine, and increased leukocyte-endothelium adhesiveness [@bib6], cardinal features of the early phase of endothelial dysfunction commonly seen in atherosclerosis.

Insulin resistance underlies vascular disturbances in humans and rodents [@bib4], [@bib7], [@bib8], [@bib9], [@bib10]. Heterozygous insulin receptor knockout mice develop systemic insulin resistance with reduced basal and insulin-stimulated NO release [@bib11]. Moreover, ablating insulin receptors in endothelial cells impairs phosphatidylinositol 3-kinase-dependent insulin signaling pathways without affecting glucose homeostasis and blood pressure under basal conditions [@bib12].

The carcinoembryonic antigen-related cell adhesion molecule-1, CEACAM1, is a plasma membrane glycoprotein that undergoes phosphorylation by the insulin receptor [@bib13]. It regulates insulin action by promoting receptor-mediated insulin uptake and degradation in the hepatocyte, the main mechanism of insulin clearance [@bib14]. Consistently, *Cc1*^*−/−*^ mice with global deletion of *Ceacam1* exhibit hyperinsulinemia caused by impaired insulin clearance, followed by insulin resistance, which is systemically manifested at 5--6 months of age when the mice are propagated on the C57BL/6 mice [@bib15], [@bib16]. Consistent with the lipogenic effect of hyperinsulinemia [@bib17], *Cc1*^*−/−*^ mice exhibit increased hepatic lipid production and redistribution to white adipose tissue and visceral obesity [@bib18]. These metabolic abnormalities were all reversed by liver-specific rescuing of CEACAM1 in *Cc1*^*−/−*^ mice [@bib19]. Persistence of insulin resistance in the presence of nicotinic acid, a lipolysis blocker, confirmed that insulin resistance precedes lipolysis, and is mainly driven by chronic hyperinsulinemia that is caused by impaired CEACAM1-dependent insulin clearance pathways in these null mice [@bib19].

In addition to their altered metabolic phenotype, *Cc1*^*−/−*^ mice develop endothelial and vascular disturbances, including increased basal vascular permeability [@bib20]. In large vessels, they exhibit low basal NO levels, defective endothelial NO-dependent relaxation of aortic rings in response to acetylcholine, and the development of small intimal plaque-like lesions in the absence of hypercholesterolemia, in addition to fibrosis, increased inflammatory infiltration and leukocytes recruitment to the aorta when fed a standard chow diet at \>6 months of age [@bib21]. They also manifest higher systolic blood pressure and activated renin--angiotensin--aldosterone system (RAS) following insulin resistance at 6 months of age [@bib22].

To address the role of impaired hepatic insulin clearance in the pathogenesis of cardiovascular abnormalities, the current studies examined whether global *Ceacam1* deletion causes cardiac and endothelial dysfunctions and whether this is reversed by liver-specific transgenic CEACAM1 reconstitution in order to determine the role of defective hepatic insulin clearance in the pathogenesis of cardiovascular disease.

2. Materials and methods {#sec2}
========================

2.1. Mice generation {#sec2.1}
--------------------

The generation of C57BL/6.*Cc1*^*−/−xliver*+^ mice harboring rescuing of CEACAM1 exclusively in the liver of *Cc1*^*−/−*^ mice has been described [@bib19]. Briefly, *Cc1*^*−/−*^ mice [@bib15], [@bib16] were crossed with L-CC1 mice with Apolipoprotein A1-driven liver-specific overexpression of wild-type rat *Ceacam1* gene [@bib23]. Intercrossing the progeny produced several genotypes, including those used in these studies: *Cc1*^*−/−*^ with the transgene (*Cc1*^*−/−xliver*+^) and their control littermates: *Cc1*^*−/−*^ and *Cc1*^+*/*+^ without the transgene.

Male mice (6--9 months of age) were kept in a 12 h-light/dark cycle and fed *ad libitum* a standard chow diet [@bib23]. Unless otherwise mentioned, mice were anesthetized using an intraperitoneal injection of pentobarbital (1.1 mg/kg BW). At the end of the experiments, mice were euthanized by CO~2~ asphyxiation. All procedures were approved by the Institutional Animal Care and Utilization Committee at the University of Toledo College of Medicine and at the Heritage College of Osteopathic Medicine in compliance with the guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication NO. 85-23, revised 1996, updated 2011).

2.2. Tissue, plasma and urine biochemistry {#sec2.2}
------------------------------------------

Plasma was derived from retro-orbital venous blood drawn at 1100 h after an overnight fast [@bib15] to determine levels of insulin (Linco Research), C-peptide (Mouse Ultrasensitive ELISA kit, Alpco), endothelin-1 (ET-1) (Abcam, ELISA ab133030), IL-6 (Abcam, ELISA ab100712), TNFα (Abcam, ELISA ab100747) and prostaglandin 2 (PGE2) (Abcam, ELISA ab133021). Plasma and tissue levels of NO was assessed using a Nitrate/Nitrite Fluorometric Assay Kit (Cayman Chemical, Cat\#780051), and fluorescence was measured by the Synergy H1 Hybrid Microplate Reader (BioTek Instruments, Winooski, VT) at 360 nm excitation and 430 nm emission wavelengths. Tissue triacylglycerol level, urine albumin (Albuwell Exocell), and creatinine levels (Cayman) were assessed as described [@bib15], [@bib16], [@bib22].

2.3. Fatty acid synthase activity {#sec2.3}
---------------------------------

As previously described [@bib19], tissues were homogenized and fatty acid synthase activity (FASN) was measured in the supernatant by adding a reaction mix containing 0.1 μCi \[^14^C\] malonyl-CoA (Perkin--Elmer) and 25 nmol malonyl-CoA in the absence or presence of 500 μM NADPH (Sigma--Aldrich) [@bib24]. The reaction was stopped with 1:1 chloroform:methanol solution and samples were centrifuged, butanol-extracted, and counted. FASN activity was calculated as cpm of \[^14^C\] incorporated Bq/μg cell lysates.

2.4. Oxidative stress {#sec2.4}
---------------------

NADP/NADPH ratio was assessed using Fluorescent NADP/NADPH detection kit (Cell Technology). Fluorescence with excitation at 530 nm and emission at 590 nm was measured using fluorescence plate reader. The concentration was determined using the slope equation generated by the standard. NADP/NADPH was calculated as a ratio of (total NADP minus NADPH) divided by NADPH.

2.5. Endothelial function {#sec2.5}
-------------------------

Mesenteric arterioles of 3rd order were isolated from anesthetized mice and placed into ice-cold phosphate-buffered saline (PBS) while excising surrounding connective and adipose tissue. Mesenteric arteriole rings (≈2 mm) were mounted isometrically under a resting force of 1.5 mN in tissue chambers of the M-series myograph system (Radnoti LLC) containing an oxygenated Krebs--Henseleit (K−H) buffer warmed to 37 °C. Rings were allowed to equilibrate for 90 min and maximal contractions to 100 mM KCl were used for normalization. Dose-responses were tested using log-based addition of phenylephrine (3 nM--10 μM). An EC~50~ of phenylephrine was added to contract the rings and dose--response was tested using the endothelial-dependent vasodilator acetylcholine (10 nM--3 μM). Endothelial-independent vasodilation was assessed using sodium nitroprusside (1 nM--100 μM). Rings were rinsed with fresh K--H buffer between each test until they returned to baseline resting tension.

2.6. Leukocytes adhesion {#sec2.6}
------------------------

For large vessels, blood was drawn via cardiac puncture and collected into K2-EDTA. As described [@bib21], leukocytes were isolated using a double-density Percoll gradient (500 g, 35 min, room temperature). PMN bands were suspended in serum-free DMEM, and fluorescently labeled using a PKH26GL staining kit, (Sigma--Aldrich). Labeled cells were co-incubated with the isolated thoracic aortic 4 mm-segments (in DMEM-supplemented with 10% fetal bovine serum (FBS) and kept at 4 °C before switching to 37 °C for an hour and leukocytes added). Shear stresses were applied by means of an orbital shaker platform heated to 37 °C for 60 min. Aortic segments were removed and PBS-washed, placed on a glass microscope slide for immersion oil. Leukocytes adhering to the endothelium were observed at 200×-magnification using an epifluorescent microscope. 3--4 fields/aorta were used and findings expressed as total number of cells/microscopic field.

To measure leukocyte adhesion in the microcirculation, quantitative intravital microscopy (IVM) of the mesentery was carried out as described [@bib25]. Four distal loops of ileal tissue, exteriorized through a midline incision laparotomy, were superfused with 37 °C K--H buffer in an intravital microscopy Plexiglas chamber attached on the stage of an Eclipse FN1 Physiostation Microscope (Nikon Corporation). Relatively straight, unbranched segments of post-capillary venules with lengths of \>100 μm and diameters between 25 and 40 μm were used. Observation of the mesenteric microcirculation was made with 20× salt water-immersion lens. Images were projected by high-resolution, intensified video cameras (XR-Mega-10 EX ICCD; Stanford Photonics) onto a high-resolution, color video monitor (Multiscan 200-sf, Sony) and the image recorded on a WIN-XP Imaging Workstation. Data were analyzed using computerized imaging software (Micro-Manager). Leukocyte adherence was defined as the number of leukocytes firmly adhered to 100 μm-length of endothelium for at least 30 s.

2.7. Immunofluorescence analysis of aortic roots {#sec2.7}
------------------------------------------------

Mice were perfused through the left ventricle with 4% (wt/vol) paraformaldehyde as described [@bib26]. Briefly, the aortic root was embedded in OCT medium, frozen and cut in 10 μm-sections onto Fisher Superfrost Plus-coated slides, fixed and incubated with anti-VCAM-1 antibody (Southern Biotech; 1:100) followed by anti-rat Alexa-fluor 555 (Cell Signaling, 1:2000, 1 h). In the negative control, VCAM-1 antibody was replaced by an equivalent dilution of normal rat serum (NRS).

2.8. Echocardiography {#sec2.8}
---------------------

Transthoracic echocardiography was performed using an Acuson System equipped with a 15-mHz transducer. Mice were anesthetized with 1--2% isoflurane by inhalation with heart rate (360--500 beats/min) and core temperature (36--37 °C) continuously being monitored. Cardiac geometry and functional parameters \[wall thickness and left ventricular cardiac function (ejection fraction and fractional shortening)\] were measured from images obtained using two-dimensional B-Mode and M-mode views. Doppler ultrasound of mitral and aortic flow was obtained to determine the myocardial performance index (MPI) (or Tei index), calculated as: (IVRT + IVCT)/ET.

2.9. Heart histology {#sec2.9}
--------------------

Hearts were fixed by 10% Formalin, paraffin-embedded and sectioned into 4 μm consecutive sections to be stained by hematoxylin and eosin (H&E). Myocyte size analysis was performed under microscopic examination of H&E stained sections at 20× magnification. The area of each myocyte was assessed and the average area/microscopic field/section were calculated. Images were collected using NIS-Element BR.1 software. Because processing of paraffin-embedded sections alters the original tissue thickness and causes shrinkage, we performed simultaneous processing of the sections from all mouse groups to be able to carry out relative comparisons of myocyte areas in the specimens examined in these studies.

2.10. Primary cardiac cells {#sec2.10}
---------------------------

Cardiac myocytes were isolated from 2 to 3 months old mice as described [@bib27]. Briefly, mice were anesthetized with an intraperitoneal injection of pentobarbital as above. The descending aorta was cut and the heart was immediately flushed by injecting the right ventricle with 7 ml of 5 mmol/l EDTA-supplemented perfusion buffer (130 mmol/l NaCl, 5 mmol/l KCl, 0.5 mmol/l NaH~2~PO~4~, 10 mmol/l HEPES, 10 mmol/l Glucose, 10 mmol/l2,3-butanedione monoxime (BDM), 10 mmol/l Taurine). Following clamping the ascending aorta, the heart was removed and transferred to a 60 mm-dish before the left ventricle was sequentially perfused with 10 ml of EDTA-supplemented perfusion buffer, followed by 3 ml of 1 mmol/l MgCl~2-~supplemented perfusion buffer, and 30--50 ml of collagenase buffer \[collagenase type II and type IV (0.5 mg/ml) (Worthington) in MgCl~2~-perfusion buffer\]. Following assessment of myocyte yield and percentage of viable rod-shaped cells using a hemocytometer, the cell pellet containing myocytes was resuspended in pre-warmed plating media M199 (Gibco) supplemented with 5% fetal bovine serum (FBS), 10 mmol/l BDM (Sigma Aldrich), and 1% Penicillin--Streptomycin (Gibco), and plated on a laminin (5 μg/ml) pre-coated 6-well tissue culture plates and placed in a humidified tissue culture incubator (37 °C, 5% CO~2~) for 1 h. Media was then replaced with fresh, pre-warmed culture media (M199 Gibco), supplemented with 0.1% BSA (Sigma Aldrich), BDM (10 mmol/l), and 1% Penicillin Streptomycin for 24 h before myocytes were collected and analyzed.

Cardiac endothelial cells were isolated from 2-month-old mice using 2 mg/ml Collagenase A (Roche) dissolved in Dulbecco\'s Phosphate Buffered Saline containing CaCl~2~ and MgCl~2~ (Gibco), as described [@bib28]. Cells were sorted by binding to anti-mouse CD31 Dynabeads immobilized on the tube wall using Magnetic Particle Concentrator DynaMag™-15. Immuno-selected CD31-positive cells were resuspended in 8 ml growth medium \[DMEM (Gibco) containing 0.01% heparin and 10% Bovine Endothelial Cell Growth Supplement-ECGS (Cell Applications), 20% FBS and 1% Penicillin--Streptomycin\] and plated on a 10 cm plate coated with 0.1% gelatin in a humidified tissue culture incubator (37 °C, 5% CO~2~). Thereafter, Growth medium was replaced every other day until cells reached ∼80% confluency at which point, they were trypsinized and incubated with rat anti-mouse CD102-coupled Dynabeads (Invitrogen) and immobilized on the tube wall as above, washed, resuspended, and plated in 10 cm gelatin-coated plates.

2.11. Western blot analysis {#sec2.11}
---------------------------

Western blot analysis was performed using 1:1000 of the following polyclonal antibodies from Cell Signaling (Danvers, MA) against: phospho-Akt (Ser 473), Akt, phospho-p44/42 MAPK (Thr 202/Tyr204), p44/42 MAPK, phospho-eNOS (Ser1177), eNOS, phospho-Foxo1 (Ser256), Foxo1, phospho-IRS1 (Ser612), IRS1, Shc, and VCAM-1. We also used antibodies against phospho-insulin receptor beta subunit (pIRβ) (phospho-Y1361), IRβ (Abcam, Cambridge, MA); and cleaved Caspase 3 (EDM Milipore, Billerica, MA). As previously shown [@bib19], we used custom-made rabbit polyclonal antibodies Ab 3759 against the mouse CEACAM1 extracellular domain, the rat CEACAM1 (αP3\[Y488\]) and phospho-CEACAM1 (α-pCC1) mouse antibodies (Bethyl Laboratories, Montgomery, TX). For normalization, α/β-tubulin antibody (Cell Signaling) was used at 1:5000 dilution. Blots were incubated with horseradish peroxidase-conjugated sheep anti-mouse IgG or donkey anti-rabbit IgG antibody (GE Healthcare Life Sciences, Amersham, Sunnyvale, CA) and subjected to enhanced chemiluminescence (ECL, Amersham Pharmacia).

For co-immunoprecipitation experiments, polyclonal antibodies against Shc (B-9) (Santa Cruz Biotechnology, Dallas, TX) and IRS1 (Cell signaling) were used to immunoprecipitate proteins from tissue lysates. To avoid detection of the antibody heavy chain, membranes were incubated with horseradish peroxidase-conjugated IgG fraction monoclonal mouse anti-rabbit IgG, light chain specific (Cat \# 211-032-171, Jackson Immuno-Research laboratories).

2.12. Quantitative real time-PCR {#sec2.12}
--------------------------------

cDNA was synthesized using Superscript III (Bio-Rad), and qRT-PCR was performed using Fast SYBR Green Master Mix by the ABI StepOnePlus Real-Time PCR System (Applied Biosystems), as described [@bib23]. Primers were used at a final concentration of 10 μΜ ([Table S1](#appsec2){ref-type="sec"}) and mRNA was normalized to 18S.

2.13. Statistical analysis {#sec2.13}
--------------------------

Parametric data were analyzed by one-way analysis of variance (ANOVA) with Tukey\'s test for multiple comparisons. Nonparametric data were analyzed by Kruskal--Wallis test with Dunn\'s correction for multiple pairwise comparisons. Statistical analysis was performed using GraphPad Prism-6 software.

3. Results {#sec3}
==========

3.1. Hepatic-specific rescuing of CEACAM1 {#sec3.1}
-----------------------------------------

qRT-PCR analysis detected mouse mRNA (m*Cc1*) in the heart, as well as the cardiac endothelial cells and myocytes of wild-type *Cc1*^+*/*+^, but not *Cc1*^*−/−*^ or *Cc1*^*−/−xliver*+^ mice ([Table S2](#appsec2){ref-type="sec"}). Rat mRNA (r*Cc1*) expression was restricted to the liver of *Cc1*^*−/−xliver*^ mice ([Table S2](#appsec2){ref-type="sec"}), as previously shown [@bib19]. Consistently, Western blot analysis detected endogenous mouse CEACAM1 (mCC1) in the liver of *Cc1*^+*/*+^, but not *Cc1*^*−/−*^ or *Cc1*^*−/−xliver*+^ mice ([Figure 1](#fig1){ref-type="fig"}A). In contrast, immunoblotting with rat CEACAM1 antibody (Ib: α-rCC1) revealed transgenic rat CEACAM1 expression in the liver of *Cc1*^*−/−xliver*+^ ([Figure 1](#fig1){ref-type="fig"}A). As previously shown [@bib19], rat CEACAM1 protein was not detected in extra-hepatic tissues of *Cc1*^*−/−xliver*+^ mice, including the heart and aorta ([Figure 1](#fig1){ref-type="fig"}A).Figure 1Metabolic phenotype. (A) Protein levels of mouse (mCC1) and rat CEACAM1 (rCC1) were analyzed by immunoblotting (Ib) with either a polyclonal antibody against mouse (upper gel), or rat CEACAM1 (middle gel). The lower part of the blot was immunoblotted with an antibody against Tubulin to normalize for protein loading. The apparent molecular weight (kDa) is indicated at the right hand-side of each gel. Gels represent more than two separate experiments performed on different mice per group. (B) Retro-orbital blood was drawn from *Cc1*^+/+^ (white), *Cc1*^−/−^ (black) and *Cc1*^*−/−xliver*+^(gray) mice (n ≥ 5 mice/genotype; 7-to-8 months of age) to assess plasma insulin (*i*), steady-state C-peptide/insulin molar ratio as measure of insulin clearance (*ii*), non-esterified fatty acids (NEFA) (*iii*), PGE2 (*iv*), IL-6 (*v*) and TNFα (*vi*). Assays were performed in triplicate. Values are expressed as mean ± SEM. \**P* ≤ 0.05 versus *Cc1*^+/+^, †*P* ≤ 0.05 *Cc1*^*−/−xliver*+^ versus *Cc1*^−/−^.Figure 1

3.2. *Cc1*^*−/−*^, but not *Cc1*^*−*/*−*xliver+^ mice, exhibit abnormal endothelium-dependent relaxation {#sec3.2}
--------------------------------------------------------------------------------------------------------

*Cc1*^*−/−*^ mice continues to exhibit chronic hyperinsulinemia at 8 months of age ([Figure 1](#fig1){ref-type="fig"}B*i*) resulting from impaired insulin clearance (steady-state C-peptide/insulin molar ratio) ([Figure 1](#fig1){ref-type="fig"}B*ii*). Hyperinsulinemia caused insulin resistance, as demonstrated by hyperinsulinemic-euglycemic clamp analysis [@bib15], [@bib19], and elevated plasma non-esterified fatty acids (NEFA) ([Figure 1](#fig1){ref-type="fig"}B*iii*). As recently reported [@bib19], these metabolic abnormalities were all reversed by rescuing CEACAM1 exclusively in the liver of *Cc1*^*−/−xliver*+^ mice ([Figure 1](#fig1){ref-type="fig"}B).

*Cc1*^*−/−*^ manifested elevated systolic blood pressure and kidney dysfunction starting at 6 months of age in association with increased intrarenal RAS activity [@bib22]. Consistent with hemodynamic changes associated with elevated RAS activity, *Cc1*^*−/−*^ mice manifested albuminurea ([Figure 2](#fig2){ref-type="fig"}A*i*) and a higher albumin-to-creatinine ratio (UACR) ([Figure 2](#fig2){ref-type="fig"}A*ii*), which was reversed by liver-specific rescuing of *Ceacam1*.Figure 2Endothelium-dependent relaxation in mesenteric arterioles. (A) Urine albumin levels (*i*) and urine albumin-to-creatinine ratio (UACR) (*ii*) were determined in 6 month-old *Cc1*^+/+^ (white), *Cc1*^−/−^ (black) and *Cc1*^*−/−xliver*+^ mice (gray) (n = 6--7/genotype). Values are expressed as mean ± SEM. (B) Nitric oxide (NO) release was determined in phenylephrine (PE)-pre-contracted arterioles (*i*), following stimulation with acetylcholine (Ach) (*ii*) and sodium nitroprusside (SNP) (*iii*) from 8 to 9 month-old mice (n = 5--6/genotype). Values are expressed as mean ± SEM. \**P* ≤ 0.05 versus *Cc1*^+/+^ and †*P* ≤ 0.05 versus *Cc1*^−/−^. (C) Plasma NO, (D) plasma endothelin-1 (Et-1) and (E) aortic NO levels were assayed in triplicate in n ≥ 5 mice/genotype (7-to-8 months of age). Values are expressed as mean ± SEM. In A--E, \**P* ≤ 0.05 versus *Cc1*^+/+^, †*P* ≤ 0.05 *Cc1*^*−/−xliver*+^ versus *Cc1*^−/−^.Figure 2

Because elevated RAS is also associated with endothelial dysfunction [@bib29], we next examined the %vasorelaxation in rings from mesenteric arterioles or vessel function with 100 mM KCl and log-based additions of acetylcholine (Ach) ([Figure 2](#fig2){ref-type="fig"}B*ii*) and sodium nitroprusside (SNP) ([Figure 2](#fig2){ref-type="fig"}B*iii*) normalized to maximum contraction in response to phenylephrine (PE) ([Figure 2](#fig2){ref-type="fig"}B*i*). Unlike the insignificant effect of nitroprusside ([Figure 2](#fig2){ref-type="fig"}B*iii*), the Emax of endothelial-dependent vasodilation of phenylephrine-precontracted rings in response to acetylcholine was increased in *Cc1*^−/−^ relative to *Cc1*^+/+^ mice ([Figure 2](#fig2){ref-type="fig"}B*ii*). This was prevented in *Cc1*^*−*/*−*xliver+^ transgenics ([Figure 2](#fig2){ref-type="fig"}B*ii*). Thus, endothelial-dependent vasodilation was impaired in *Cc1*^−/−^ in association with the loss of CEACAM1 in liver. Consistent with reduced NO bioavailability in association with impaired vasodilation in response to acetylcholine [@bib6], basal plasma NO levels were lower in *Cc1*^−/−^ than *Cc1*^+*/*+^ wild-types ([Figure 2](#fig2){ref-type="fig"}C), as previously shown [@bib21]. This was accompanied by a reciprocal increase in plasma endothelin-1 (ET-1) levels ([Figure 2](#fig2){ref-type="fig"}D), which could in part stem from lower plasma PGE2 levels ([Figure 1](#fig1){ref-type="fig"}B*iv*), as reported [@bib30], [@bib31]. Liver-specific CEACAM1 rescuing restored plasma NO and ET-1 levels ([Figure 2](#fig2){ref-type="fig"}C--D; *Cc1*^*−*/*−*xliver+^ versus *Cc1*^−/−^ mice).

3.3. *Cc1*^*−/−*^, but not *Cc1*^*−*/*−*xliver+^ mice, exhibit an increase in inflammation and leukocyte adhesion {#sec3.3}
-----------------------------------------------------------------------------------------------------------------

Because in addition to low NO bioavailability, inflammation and leukocyte-endothelium adhesion increase in the early phase of endothelial dysfunction [@bib6], we further investigated the implication of *Ceacam1* deletion in endothelial function by carrying out intravital microscopy to measure leukocyte adhesion. As shown in [Figure 3](#fig3){ref-type="fig"}A*i*, the venular endothelium of *Cc1*^*−/−*^ displayed an increase in adhesiveness to circulating leukocytes, as evidenced by the ∼2.5-fold increase in leukocyte adhesion in mesenteric post-capillaries. This was curbed by restoring CEACAM1 expression in liver.Figure 3Leukocyte-endothelium adhesion in aorta. (A) Mesenteric venules (*i*) and aortae (*ii*) of 8--9 month-old *Cc1*^+/+^ (white bar), *Cc1*^−/−^ (black bar) and *Cc1*^*−/−xliver*+^ mice (gray bar) (n = 5--7/genotype) were removed and their leukocytes--endothelium interaction was assayed. Values are expressed as mean ± SEM. \**P* ≤ 0.05 versus *Cc1*^+/+^ and †*P* ≤ 0.05 *Cc1*^*−/−xliver*+^ versus *Cc1*^−/−^ mice. (B) Western blot analysis of lysates from aorta of 8-month-old mice using α-VCAM-1 antibody to immunoblot (Ib) the upper half and α-tubulin to immunoblot the lower half for normalization against the amount of total proteins loaded. The apparent molecular weight (kDa) is indicated at the right hand-side of each gel. Gels represent more than two separate experiments performed on different mice per group. (C) Immunofluorescence analysis of VCAM-1 expression in the aortic root of 9 month-old mice (n = 5/genotype). DAPI blue staining was used to detect nuclei and visualize tissue context. Red VCAM-1 staining was higher in sections from *Cc1*^−/−^ mice (both *ii* at 10× and *ii'* in the enlarged field at 20×) versus *Cc1*^+*/*+^ (*i*) and *Cc1*^*−/−xliver*+^ (*iii*). To control for VCAM-1 antibody specificity, some *Cc1*^−/−^ sections were incubated with normal rat serum (NRS) as a non-specific primary antibody. L: The luminal aspect of the vessels was included for reference.Figure 3

Parallel *ex-vivo* experiments with leukocytes isolated from *Cc1*^−/−^ aortae demonstrated a significantly higher (∼3.5-fold) pro-adhesive phenotype compared with wild-type controls ([Figure 3](#fig3){ref-type="fig"}A*ii*), as previously reported [@bib21]. Restoring CEACAM1 expression in liver normalized this phenotype in *Cc1*^*−*/*−*xliver+^ mice, bringing the number of adhering leukocytes to levels comparable to that in control mice.

Consistent with increased adhesion of leukocytes both in microcirculation and large conduit arteries in *Cc1*^*−/−*^ mice, the mRNA ([Table S3](#appsec2){ref-type="sec"}) and protein levels of VCAM-1, a critical mediator of leukocytes recruitment to the endothelium [@bib32], [@bib33], was higher in *Cc1*^−/−^ than *Cc1*^+/+^ aortae, as shown by Western blot ([Figure 3](#fig3){ref-type="fig"}B) and immunofluorescence analysis of aortic root sections ([Figure 3](#fig3){ref-type="fig"}C*ii--ii*′ versus C*i*). Liver-specific rescuing of CEACAM1 restored normal aortic *Vcam-1* mRNA ([Table S3](#appsec2){ref-type="sec"}) and VCAM-1 protein levels ([Figures 3](#fig3){ref-type="fig"}B and C*iii*). Similarly, the mRNA levels of other cell adhesion molecules such as *Icam-1* and *P-selectin* were ∼2-fold higher in *Cc1*^−/−^ than *Cc1*^+/+^ and *Cc1*^*−*/*−*xliver+^ mice ([Table S3](#appsec2){ref-type="sec"}).

Plasma IL-6 and TNFα levels were elevated in *Cc1*^−/−^ relative to *Cc1*^+/+^ and *Cc1*^*−*/*−*xliver+^ mice ([Figure 1](#fig1){ref-type="fig"}B*v* and B*vi*, respectively). Similarly, the mRNA levels of macrophage markers (*F4/80 and Cd68*) and TNFα were higher in the aortae of *Cc1*^−/−^ than *Cc1*^+/+^ and *Cc1*^*−*/*−*xliver+^ mice ([Table S3](#appsec2){ref-type="sec"}). Consistent with increased TNFα infiltration in association with aortic lipid accumulation in vascular disease [@bib34], the mRNA levels of the fatty acid transporter *Cd36* and fatty acid synthase (*Fasn*) were elevated in *Cc1*^−/−^ aortae ([Table S3](#appsec2){ref-type="sec"}), as predicted from hyperinsulinemia-driven activation of lipogenic gene expression [@bib17]. In support of enhanced oxidative stress by TNFα, *Cc1*^−/−^ aortae manifested lower basal aortic NO levels ([Figure 2](#fig2){ref-type="fig"}E) and higher mRNA levels of oxidative stress genes (*Nox1*, *Nox4* and *gp91*) than their *Cc1*^+/+^ counterparts ([Table S3](#appsec2){ref-type="sec"}). These parameters were all normalized in *Cc1*^*−*/*−*xliver+^ mice ([Figure 2](#fig2){ref-type="fig"}E and [Table S3](#appsec2){ref-type="sec"}).

3.4. *Cc1*^*−/−*^ mice manifest blunted aortic insulin signaling {#sec3.4}
----------------------------------------------------------------

Because altered insulin action reduces NO bioavailability and elevates ET-1 levels to tip the balance towards reducing vasodilation [@bib2], [@bib4], we then examined insulin signaling in aortic lysates. To this end, mice were subjected to an overnight fast (F) prior to refeeding for 7 h to release insulin ([Figure 4](#fig4){ref-type="fig"}A). As expected from chronic hyperinsulinemia [@bib35], immunoblotting (Ib) with an antibody against the beta subunit of the insulin receptor (α-IRβ) and against tubulin (α-tubulin) to normalize against total protein loaded showed a 50% decrease in the insulin receptor protein level in the aorta of *Cc1*^−/−^ relative to *Cc1*^+*/*+^ mice ([Figure 4](#fig4){ref-type="fig"}B middle gel against lower gel), as we have shown in the liver and hypothalamus [@bib19]. This reduced IRβ phosphorylation, as immunoblotting with α-phospho-IRβ antibody revealed ([Figure 4](#fig4){ref-type="fig"}B, top gel). It also reduced the phosphorylation of downstream signaling molecules such as IRS1, Akt, eNOS, and Foxo1 ([Figure 4](#fig4){ref-type="fig"}C--F). Rescuing CEACAM1 in the liver reversed basal hyperinsulinemia ([Figure 4](#fig4){ref-type="fig"}A) and subsequently, the level and phosphorylation of IRβ ([Figure 4](#fig4){ref-type="fig"}B) and of its downstream signaling molecules ([Figure 4](#fig4){ref-type="fig"}C--F). Together, this indicates that hyperinsulinemia contributed to dysregulated insulin-dependent activation of eNOS, and subsequently, lower NO production in *Cc1*^−/−^ aortae.Figure 4Insulin signaling in aorta. (A) Mice (8 months of age, n = 6/genotype/treatment) were fasted (F) overnight and refed for 7 h (RF) before retro-orbital venous blood was drawn and plasma insulin levels were assayed, as indicated in the graph \[*Cc1*^+/+^ (white for F and right diagonal stripes for RF), *Cc1*^−/−^ (black for F and vertical stripes for RF), and *Cc1*^*−/−xliver*+^ (gray for F and left diagonal stripes for RF)\]. Values are expressed as mean ± SEM. \**P* ≤ 0.05 versus *Cc1*^+/+^, †*P* ≤ 0.05 *Cc1*^*−/−xliver*+^ versus *Cc1*^−/−^ mice/treatment group and ‡*P* ≤ 0.05 *Cc1*^*−/−*^ versus others/treatment group. (B) Western analysis of lysates from aortae was performed to assess insulin receptor protein level (Ib: α-IRβ) and phosphorylation (Ib: α-pIRβ). The lower half of the gel was used to immunoblot with α-Tubulin antibody for protein normalization. (D--G) Lysates were subjected to Western blot analysis using antibodies against phosphorylated (p) Akt (D), eNOS (E), Foxo1 (F) and MAPkinase (G) (top gels), and with antibodies against the proteins to control for loading (lower gels). (B) Some aliquots were subjected to immunoprecipitation (Ip) with α-IRS1 antibody followed by immunoblotting with antibodies against phosphor-IRS1 (pIRS1, top gel), IRβ (middle gel), or IRS1 (bottom gel). (H) Other aortic lysates were subjected to immunoprecipitation (Ip) with α-Shc antibody followed by immunoblotting (Ib) with antibodies against phospho-CEACAM1 (pCC1, top gel), IRβ (middle gel) or Shc (lower gel). The apparent molecular weight (kDa) is indicated at the right hand-side of each gel. Gels represent 2 separate experiments performed on different mice/genotype/treatment.Figure 4

In contrast, insulin induced MAPKinase phosphorylation to a larger extent in *Cc1*^−/−^ than *Cc1*^+*/*+^ and *Cc1*^*−*/*−*xliver+^ aortae ([Figure 4](#fig4){ref-type="fig"}G), in parallel to a higher binding of Shc to IRβ in aortic lysates of the hyperinsulinemic *Cc1*^*−/−*^ by comparison to its normo-insulinemic counterparts, as shown by the higher level of IRβ detected by immunoblotting the Shc immunopellet (Ip) with α-IRβ antibody ([Figure 4](#fig4){ref-type="fig"}H, middle gel). This occurred in parallel to the reciprocal decrease in IRS1 binding to IRβ, as shown by immunoblotting the IRS1 immunopellet with α-IRβ antibody ([Figure 4](#fig4){ref-type="fig"}B, middle gel). Because Shc competes with IRS1 for NPEY960 in the juxtamembrane domain of the insulin receptor [@bib36], it is conceivable that lower IRS1 phosphorylation and binding to IRβ gave way to more Shc binding to IRβ in *Cc1*^*−/−*^ aortae, which in turn led to more coupling of the Ras/MAPkinase pathway to the receptor, and its superior activation in *Cc1*^*−/−*^ relative to *Cc1*^+*/*+^ and *Cc1*^*−*/*−*xliver+^ aortae. This could contribute to the higher mRNA levels of ET-1 *(Et-1)* [@bib2], [@bib4] and its -A and -B receptors in the aortae of *Cc1*^*−/−*^ mice as compared to the other mouse groups ([Table S3](#appsec2){ref-type="sec"}. *Etar* and *Etbr*). Consistent with the lower vasodilation tone, the ratio of *Etar*/*Etbr* was ∼5-fold higher in the aortae of *Cc1*^*−/−*^ as compared to the other mouse groups ([Table S3](#appsec2){ref-type="sec"}).

3.5. *Cc1*^*−/−*^ mice manifest altered cardiac performance and myocardial hypertrophy {#sec3.5}
--------------------------------------------------------------------------------------

Obesity and hypertension are associated with left ventricular hypertrophy [@bib37], [@bib38]. Thus, we next performed transthoracic cardiac ultrasound to assess cardiac structure and function in 6 month-old male mice. Echocardiography demonstrated increased septal wall thickness (SWTd) ([Figure 5](#fig5){ref-type="fig"}A*i*) and posterior wall thickness (PWTd) ([Figure 5](#fig5){ref-type="fig"}A*ii*) in *Cc1*^*−/−*^, but not *Cc1*^*−*/*−*xliver+^ mice. Moreover, the relative wall thickness was also elevated in null mutants, but not in *Cc1*^*−*/*−*xliver+^ mice ([Table S4](#appsec2){ref-type="sec"}). Together, this suggested left ventricular hypertrophy in *Cc1*^−/−^ mice, as further shown by the M-mode representation of the heart ([Figure 5](#fig5){ref-type="fig"}B*i*). Cardiac hypertrophy in *Cc1*^−/−^ by comparison to *Cc1*^+/+^ and *Cc1*^*−*/*−*xliver+^ mice was confirmed by the higher heart weight/tibial length ratio ([Figure 6](#fig6){ref-type="fig"}A) and the elevation in the mRNA levels of cardiac-hypertrophy markers \[Atrial natriuretic factor (Anp); β-myosin heavy chain (*β-*Mhc) and Brain natriuretic peptide (*Bnp*)\] ([Figure 6](#fig6){ref-type="fig"}B*i--iii*), in *Cc1*^−/−^ mice with reversal of these features in *Cc1*^*−/−xliver*+^ mice. Consistently, histological examination of H&E-stained myocardial sections ([Figure 6](#fig6){ref-type="fig"}C) further revealed a significantly enlarged myocyte area in *Cc1*^−/−^ as compared to that of *Cc1*^+/+^ hearts ([Figure 6](#fig6){ref-type="fig"}C*ii* versus C*i* and accompanying graph). At least in part, this could result from increased cardiomyocyte proliferation, as demonstrated by elevated mRNA levels of markers of cell growth (*Pcna*, *c-Jun* and *c-Fos*) ([Figure 6](#fig6){ref-type="fig"}D) in heart lysates. Restoring CEACAM1 expression in liver prevented myocardial hypertrophy ([Figure 6](#fig6){ref-type="fig"}C*iii versus* C*i* and accompanying graph) and cardiac cell proliferation ([Figure 6](#fig6){ref-type="fig"}D) in null mutants.Figure 5Echocardiography analysis. (A) Representative echocardiography analysis in 6 month-old *Cc1*^+/+^ (white bar), *Cc1*^−/−^ (black bar) and *Cc1*^*−/−xliver*+^ mice (gray bar) (n = 10/genotype). Septal wall thickness at end diastole (SWTd) (*i*), posterior wall thickness at end diastole (PWTd) (*ii*), fractional shortening (FS) (*iii*), myocardial performance index (MPI) (*iv*) were determined. Values are expressed as mean ± SEM. \**P* ≤ 0.05 versus *Cc1*^+/+^ and †*P* ≤ 0.05 *Cc1*^*−/−xliver*+^ versus *Cc1*^−/−^ mice. (B) (*i*) Representative M-mode of each mouse type demonstrating cardiac hypertrophy and reduced wall motion of *Cc1*^−/−^ mice. *Cc1*^*−/−xliver*+^ mice manifest normal LV geometry and function.Figure 5Figure 6Cardiac hypertrophy analysis. (A) Hearts were removed from male mice (6 month-old, n = 5/genotype), and their weight was normalized to tibial length as a measure of cardiac hypertrophy. (B) qRT-PCR analysis of mRNA of markers of hypertrophy in heart homogenates. These include *β-Mhc* (*i*), *Anp* (*ii*) and *Bnp* (*iii*) (n = 5/genotype in triplicate). (C) H&E stain of heart sections from mice (3 sections/mouse). In the accompanying graph, the average myocyte area was quantitated under the microscope at 20× magnification. (D) mRNA analysis of markers of cell proliferation in heart homogenates. These include *Pcna* (*i*), *c-Jun* (*ii*), and *c-Fos* (*iii*). Analysis was performed relative to *Gapdh* and expressed as mean ± SEM (n = 5/genotype in triplicate). In (A, B and D), values are expressed as mean ± SEM. \**P* ≤ 0.05 versus *Cc1*^+/+^ and †*P* ≤ 0.05 *Cc1*^*−/−xliver*+^ versus *Cc1*^−/−^ mice.Figure 6

Additionally, *Cc1*^−/−^ mice exhibited decreased left ventricular systolic function, as determined by reduced fractional shortening (FS) ([Figure 5](#fig5){ref-type="fig"}A*iii*), fractional shortening area (FSA), and cardiac index ([Table S4](#appsec2){ref-type="sec"}). In addition, the myocardial performance (MPI), which incorporates measures of both systolic and diastolic function, was elevated in *Cc1*^−/−^ mice ([Figure 5](#fig5){ref-type="fig"}A*iv*). Restoring CEACAM1 expression in the liver fully curbed these cardiac performance measures.

3.6. *Cc1*^*−/−*^ mice manifest fat accumulation and oxidative stress in the heart {#sec3.6}
----------------------------------------------------------------------------------

Because ectopic fat accumulation [@bib39] and oxidative stress [@bib40] cause cardiomyopathy, we then assessed these parameters in the heart. *Cc1*^−/−^ mice manifested elevated cardiac triacylglycerol levels relative to wild-types ([Figure 7](#fig7){ref-type="fig"}A), which was reversed in *Cc1*^*−/−xliver*+^ mice. This occurred in parallel to increased mRNA levels of genes involved in fatty acid transport (*Cd36*) and lipogenesis (*Fasn*) ([Table S5](#appsec2){ref-type="sec"}). *Fasn* mRNA level was also elevated in cardiac endothelial cells (not shown), likely resulting from activated transcription under hyperinsulinemic conditions [@bib17]. Consistently, FASN activity was higher in the null as compared to *Cc1*^+*/*+^ and *Cc1*^*−/−xliver*+^ mice ([Figure 7](#fig7){ref-type="fig"}B).Figure 7Lipid content, oxidative stress and apoptosis in the heart. The hearts of 6 month-old mice (n = 5/genotype) were assayed in triplicate for (A) triacylglycerol level; (B) fatty acid synthase (FASN) activity by \[^14^C\]-malonyl-CoA incorporation; (C*i*) NO content and (C*ii*) NADP/NADPH as measure of oxidative stress. \**P* ≤ 0.05 versus *Cc1*^+/+^ and †*P* ≤ 0.05 *Cc1*^*−/−xliver*+^ versus *Cc1*^−/−^ mice. (D) Heart lysates were analyzed by Western blot using caspase 3 antibody that detected the cleaved fragment of ∼20 kDa apparent molecular weight. Gels represent 2 separate experiments performed on different mice/genotype/treatment.Figure 7

The content of NO was reduced in the heart of *Cc1*^−/−^ mice ([Figure 7](#fig7){ref-type="fig"}C*i*), in parallel to an increase in oxidative stress (assessed by a rise in NADH/NADPH ([Figure 7](#fig7){ref-type="fig"}C*ii*)) and in the mRNA levels of *Nox1*, *Nox4*, and *gp91* ([Table S5](#appsec2){ref-type="sec"}). This could result in part from reduced PGE2 levels ([Figure 1](#fig1){ref-type="fig"}B*iv*), as reported [@bib41], [@bib42]. Nonetheless, all oxidative stress markers were normalized in *Cc1*^*−/−xliver*+^ mice ([Figure 7](#fig7){ref-type="fig"}C and [Table S5](#appsec2){ref-type="sec"}).

Consistent with oxidative stress causing cardiomyocyte apoptosis, Western blot analysis revealed an increase in cleaved caspase 3 levels in the heart lysates of *Cc1*^−/−^ relative to *Cc1*^+/+^ mice, but was reversed in *Cc1*^*−/−xliver*+^ mice ([Figure 7](#fig7){ref-type="fig"}D).

3.7. *Cc1*^*−/−*^ mice manifest blunted insulin signaling in heart lysates {#sec3.7}
--------------------------------------------------------------------------

We then examined whether hyperinsulinemia-driven systemic factors affected insulin signaling in *Cc1*^−/−^ heart in parallel to cardiac dysfunction. To this end, we assessed activation of insulin signaling pathway in the lysates of hearts removed from overnight fasted (F) and refed (RF) mice. Western blot analysis revealed lower IRβ protein level in *Cc1*^−/−^ than *Cc1*^+/+^ and *Cc1*^*−/−xliver*+^ heart lysates ([Figure 8](#fig8){ref-type="fig"}A, middle panel normalized to tubulin in the lower gel as marker of loaded protein). Consistently, insulin failed to induce IRβ phosphorylation in refed *Cc1*^−/−^ hearts as it did to *Cc1*^+/+^ and *Cc1*^*−/−xliver*+^ mice, when compared to their fasting state ([Figure 8](#fig8){ref-type="fig"}A, top gel). Subsequently, insulin failed to phosphorylate (and activate) downstream IRS1/Akt/eNOS pathway in refed *Cc1*^−/−^ hearts ([Figure 8](#fig8){ref-type="fig"}B--D). Together, this indicates that hyperinsulinemia contributes to dysregulated insulin-dependent activation of eNOS and subsequently, lower NO content in *Cc1*^−/−^ hearts.Figure 8Insulin signaling in the heart. The hearts were removed from the same 8 month-old fasted (F) and refed (RF) mice as in [Figure 4](#fig4){ref-type="fig"}. Western analysis was performed by immunoblotting (Ib) with antibodies against phospho-IRβ (*A*, α-pIRβ), phospho-Akt (C, α-pAkt), phospho-eNOS (D, α-peNOS), and phospho-MAPKinase (E, α-pMAPK), in addition to immunoblotting (Ib) with antibodies against IRβ, Akt, eNOS, and MAPK, respectively for normalization. In (A), the lower half of the membrane was immunoblotted with α-tubulin to normalize against protein loading (lower gel). In (B), some aliquots were subjected to immunoprecipitation (Ip) with α-IRS1 antibody followed by immunoblotting wih α-phospho-IRS1 antibody (α-pIRS1, top gel), normalized to total IRS1 (lower gel). The immunopellet was also immunoblotted with α-pIRβ antibody to detect binding between IRS1 and IRβ (middle gel). In (F), a similar co-immunoprecipitation experiment was carried out to detect phospho-CEACAM1 (pCC1) (top gel) or IRβ (middle gel) in the Shc immunopellet. The apparent molecular weight (kDa) is indicated at the right hand-side of each gel. Gels represent more than two separate experiments performed on different mice/genotype/treatment group.Figure 8

Like aortae, insulin induced MAPKinase phosphorylation to a larger extent in *Cc1*^−/−^ than *Cc1*^+*/*+^ and *Cc1*^*−*/*−*xliver+^ hearts ([Figure 8](#fig8){ref-type="fig"}E), in parallel to a higher binding of Shc to IRβ in the Shc immunopellet (Ip) ([Figure 8](#fig8){ref-type="fig"}F, middle gel). This occurred in parallel to the reciprocal decrease in IRβ in the IRS1 immunopellet ([Figure 8](#fig8){ref-type="fig"}B, middle gel). The higher Shc-IRβ binding led to more coupling of the Ras/MAPkinase pathway to the receptor, and its higher activation to cause an increase in *Et-1* mRNA levels ([Table S5](#appsec2){ref-type="sec"}) [@bib2], [@bib4]. Moreover, *Etar* and *Etbr* mRNA levels and their *Etar*/*Etbr* ratio were ∼5- to 7-fold higher in *Cc1*^*−/−*^ hearts as compared to the other mouse groups ([Table S5](#appsec2){ref-type="sec"}).

4. Discussion {#sec4}
=============

Insulin resistance is associated with cardiovascular abnormalities, including endothelial dysfunction, hypertension, and altered cardiac performance [@bib10], [@bib43], [@bib44]. The role of hyperinsulinemia in the pathogenesis of endothelial dysfunction remains unclear. Fed a standard chow diet, *Cc1*^−/−^ mice develop systemic insulin resistance at 5--6 months of age [@bib15], [@bib16], and obesity in part due to leptin resistance [@bib45]. Their vascular phenotype includes increased endothelial permeability and altered vascular remodeling [@bib20], [@bib46], elevated systolic blood pressure [@bib22], lower basal NO bioavailability and reduced vasodilatory response to acetylcholine in aortic rings [@bib21], and plaque-like lesions in large vessels in the absence of hypercholesterolemia or a significant change in lipoprotein composition [@bib21]. Together with the development of these abnormalities in the macrovasculature at \>6 months of age, the current studies demonstrated that *Cc1*^−/−^ mice also developed spontaneous endothelial dysfunction with cardiomyopathy and altered cardiac performance. This cardiovascular phenotype was reversed by liver-specific reconstitution of CEACAM1, which normalized hepatic insulin clearance and systemic insulin levels, followed by suppressing hepatic *de novo* lipogenesis and reversal of visceral obesity and lipolysis. This further assigns a key role for hyperinsulinemia-driven metabolic events in the pathogenesis of cardiovascular abnormalities in *Cc1*^−/−^ mice.

In addition to low acetylcholine-induced endothelial dependent vasodilation of phenylephrine pre-contracted aortic rings [@bib21], the current studies demonstrated reduced endothelium-dependent vasodilatory response of the resistance arterioles in *Cc1*^−/−^ mice. The altered vasodilatory response to stimuli both in small and large conduit vessels could contribute to increased production of VCAM-1 and other cell adhesion molecules [@bib33] that increase leukocyte adhesion to the endothelium, in addition to increased reactivity toward VCAM-1 [@bib32], [@bib47]. Reversal of these abnormalities by liver-specific restoration of CEACAM1 expression suggests that they occurred, at least in part, as a consequence of hyperinsulinemia caused by *Ceacam1* deletion. For instance, chronic hyperinsulinemia activates the transcription of lipogenic genes, including *Fasn*, and prevents the suppressive effect of the acute rise of insulin on FASN activity to induce lipogenesis. This in turn, promotes fat redistribution from the liver to adipose tissue to cause visceral obesity and ensuing lipolysis and systemic pro-inflammatory state in *Cc1*^−/−^ mice [@bib48]. The rise in inflammatory markers such as TNFα could induce a direct upregulatory effect on VCAM-1 expression in *Cc1*^−/−^ vessels [@bib49], [@bib50], [@bib51], thus modulating leukocyte adhesion to the endothelium. The rise in plasma NEFA could activate both the vascular endothelium [@bib52] and circulating leukocytes [@bib53], [@bib54]. For instance, reduction in endothelial-dependent relaxation in *Cc1*^*−/−*^ mice could result from elevated levels of plasma NEFA [@bib55], which impair eNOS phosphorylation, independently of Akt-mediated signaling [@bib56], and contribute to decreased NO production by reactive oxygen species-dependent mechanisms [@bib57].

*Cc1*^−/−^ mice also manifested altered cardiac performance with reduced left ventricular systolic function and left ventricular hypertrophy, consistent with the well documented association between obesity and left ventricular hypertrophy [@bib38]. Moreover, recovery of the cardiac function in *Cc1*^*−*/*−*liver+^ mice supports a significant role for systemic metabolic factors emanating from CEACAM1 deletion in liver in the cardiac phenotype of *Cc1*^−/−^ mice, including increased lipogenesis in *Cc1*^−/−^ hearts. Cardiac lipid accumulation could be caused by hyperinsulinemia-driven transcriptional induction of lipogenic genes, such as *Fasn* [@bib17], as has been shown in patients with cardiomyopathy [@bib58]. Together with elevated cardiac CD36 levels, which could mediate an increase in fatty acid uptake by endothelial cells and cardiomyocytes to promote lipid storage in the heart myocardium, this could contribute to inflammation, oxidative stress and cardiac dysfunction [@bib59].

Curbing endothelial dysfunction and other cardiovascular abnormalities of *Cc1*^−/−^ mice in response to restoring normo-insulinemia, insulin signaling, and lipid metabolism in the heart upon liver-specific rescuing of CEACAM1 underscores the significant role of hyperinsulinemia-driven lipid accumulation and insulin resistance in the pathogenesis of cardiovascular disease in *Ceacam1* null mice. This is supported by the notion that hyperinsulinemia constitutes an independent risk factor for vascular disease in humans [@bib60], in part by causing an increase in ET-1 [@bib61] and FASN levels [@bib58]. Of note, hyperinsulinemia in the absence of insulin resistance, does not suffice to promote atherosclerosis in *ApoE*^*−*/*−*^ mice with a monoallelic deletion of insulin receptors in endothelial cells that causes a reduction in insulin disposition [@bib62]. Therefore, it is conceivable that hyperinsulinemia-driven insulin resistance and fat accumulation in endothelial aortae and hearts of *Cc1*^−/−^ mice played a significant role in the pathogenesis of endothelial dysfunction and other cardiovascular abnormalities in these mice.

Mechanistically, we herein demonstrated that hyperinsulinemia caused downregulation of the insulin receptor in the aortae and heart lysates, reducing the phosphorylation of the insulin receptor and its IRS-1 substrate. The decrease in IRS-1 phosphorylation restricted Akt/eNOS/Foxo1 phosphorylation to reduce NO production in aortae and heart [@bib4]. It also allowed for more Shc binding to the receptor to mediate coupling of the Ras/MAPKinase pathway followed by its activation and increased ET-1 transcription [@bib2]. As has been reported in humans, this selective insulin resistance increased the *Etar*/*Etbr* ratio to disturb balance and mediated the vasoconstrictor function of ET-1 leading to endothelial dysfunction [@bib61].

Moreover, fed hyperglycemia could contribute to increased oxidative stress and the cardiovascular abnormalities in *Cc1*^−/−^ mice [@bib63]. Given that these mice harbor most of the metabolic risk factors of cardiovascular disease associated with insulin resistance [@bib64] that were eliminated by reconstituting CEACAM1 in the liver, we postulate that endothelial and cardiac dysfunctions in *Cc1*^−/−^ mice were a primary cardiovascular consequence of hepatic-driven, sustained hyperinsulinemia and ensuing metabolic abnormalities.

5. Conclusion {#sec5}
=============

In summary, the current study presents an *in vivo* demonstration of the link between metabolic and cardiovascular abnormalities in *Cc1*^−/−^ mice. Reversal of the cardiovascular phenotype together with normalization of insulin levels and action in *Cc1*^*−*/*−*liver+^ mice supports the role of hyperinsulinemia in regulating cardiovascular function [@bib65], [@bib66] including the liver [@bib67]. It is thus conceivable to predict that future therapy targeting hepatic CEACAM1 level and function may prove beneficial for the prevention of the cardiovascular disturbances that develop in metabolic syndrome.
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